Clinical pharmacokinetics of ranolazine.

Clinical Pharmacokinetics
Markus Jerling

Abstract

Ranolazine is a compound that is approved by the US FDA for the treatment of chronic angina pectoris in combination with amlodipine, beta-adrenoceptor antagonists or nitrates, in patients who have not achieved an adequate response with other anti-anginals. The anti-anginal effect of ranolazine does not depend on changes in heart rate or blood pressure. It acts through different pharmacological mechanisms where inhibition of the late inward sodium current (reducing calcium overload and thereby left ventricular diastolic tension) is one plausible mechanism of reduced oxygen consumption. Initial studies used an oral solution or an immediate-release (IR) capsule, but subsequently an extended-release (ER) formulation was developed to allow for twice-daily administration with maintained efficacy. Following administration of an oral solution or IR capsule, peak plasma concentrations (C(max)) are observed within 1 hour. After administration of radiolabelled ranolazine, 73% of the dose was excreted in urine, and unchanged ranolazine accounted for <5% of radioactivity in both urine and faeces. The absolute bioavailability ranges from 35% to 50%. Food has no effect on rate or extent of absorption from the ER formulation. Ranolazine protei...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Aug 1, 1973·The British Journal of Surgery·R N PughR Williams
Apr 1, 1974·Clinical Pharmacology and Therapeutics·A BreckenridgeR Gibbons
Jan 1, 1997·Pharmacology & Therapeutics·L S Kaminsky, Z Y Zhang
Apr 29, 1998·Clinical Pharmacology and Therapeutics·P J NeuvonenK T Kivistö
Aug 8, 1998·Clinical Pharmacology and Therapeutics·H WakasugiK Inui
Aug 17, 2000·Clinical Pharmacology and Therapeutics·K WestphalW Siegmund
Jun 26, 2001·British Journal of Clinical Pharmacology·K R Yeo, W W Yeo
Jan 22, 2003·Seminars in Dialysis·Albert W Dreisbach, Juan J L Lertora
Jul 10, 2003·British Journal of Clinical Pharmacology·Thomayant PrueksaritanontNathan Yu
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Bernard R ChaitmanUNKNOWN Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators
Apr 20, 2004·Journal of the American College of Cardiology·Bernard R ChaitmanUNKNOWN MARISA Investigators
Jul 10, 2004·Journal of Cardiovascular Pharmacology·Yejia SongLuiz Belardinelli
Jan 7, 2005·Clinical Pharmacokinetics·Monette M CotreauDavid J Greenblatt
Jan 27, 2005·The American Journal of Cardiology·Michel F RousseauAndrew A Wolff
Jun 14, 2005·Journal of Clinical Pharmacology·Hisham Abdallah, Markus Jerling
Sep 13, 2005·Clinical Pharmacology and Therapeutics·Markus Jerling, Hisham Abdallah

❮ Previous
Next ❯

Citations

Dec 19, 2012·Cardiovascular Drugs and Therapy·Neil J Wimmer, Peter H Stone
Jan 22, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Nael Hawwa, Venu Menon
Mar 2, 2010·Nature Reviews. Drug Discovery·UNKNOWN International Transporter ConsortiumLei Zhang
Apr 16, 2010·American Journal of Therapeutics·Chandrasekar PalaniswamyDiwakar Mohan
Apr 24, 2004·Annals of General Hospital Psychiatry·Kimberly D McLaren, Lauren B Marangell
Aug 13, 2013·Case Reports in Neurological Medicine·Jahan PorhomayonAlireza Yarahmadi
Feb 28, 2014·Case Reports in Transplantation·Joanna C MastersAshley A Feist
Oct 9, 2012·Advanced Drug Delivery Reviews·Margarida EstudanteLeslie Z Benet
May 20, 2014·Current Atherosclerosis Reports·Marco Valgimigli, Simone Biscaglia
Jun 30, 2011·Der Internist·T Meinertz, R Köster
Jul 24, 2012·Drug Development and Industrial Pharmacy·P Ravindra BabuP Jawahar Babu
Aug 25, 2012·Expert Opinion on Investigational Drugs·Stylianos Tzeis, George Andrikopoulos
Jun 15, 2015·The American Journal of Emergency Medicine·Nour AkilSameer Kamath
Jan 3, 2015·International Journal of Cardiology·Mattia CattaneoAugusto Gallino
Apr 18, 2013·Current Problems in Cardiology·Karthiek R NaralaPeter A McCullough
Feb 14, 2007·Clinical Therapeutics·Judy W M Cheng
May 30, 2008·Pacing and Clinical Electrophysiology : PACE·David K MurdockNaomi Overton
Jan 12, 2013·Pharmacotherapy·Robert A SouthardRon Blankstein
Apr 30, 2016·Clinical Pharmacology in Drug Development·Julia ZackPhil Jochelson
Aug 8, 2015·Journal of the Royal Army Medical Corps·Iain ParsonsP Rees
Nov 21, 2013·Journal of the Neurological Sciences·Federica GinanneschiAlessandro Rossi
Jul 8, 2016·Journal of Clinical Pharmacology·Bo Feng, Manthena V Varma
Aug 9, 2016·Cardiovascular Drugs and Therapy·Giacinta GuariniMario Marzilli
Mar 26, 2010·Lancet·Dobromir Dobrev, Stanley Nattel
May 24, 2014·Cardiology·Sahil KheraWilbert S Aronow
Nov 14, 2016·International Journal of Cardiology·Kinjal BanerjeeAnjan Gupta
Mar 21, 2017·British Journal of Pharmacology·Donato CappettaAntonella De Angelis
Sep 9, 2006·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Lei TianYishi Li
Sep 30, 2010·The Annals of Pharmacotherapy·Dwayne A Pierce, Amber M Reeves-Daniel
Jan 5, 2012·The Annals of Pharmacotherapy·Don N ReederDavid J Frohnapple
Oct 27, 2017·Journal of Cardiovascular Pharmacology·Helena CarstensenThomas Jespersen
Feb 28, 2014·Clinical Medicine Insights. Therapeutics·Mohammed AldakkakAmadou K S Camara
Feb 9, 2017·The Cochrane Database of Systematic Reviews·Carlos A SalazarCésar Loza Munárriz
Apr 30, 2017·American Journal of Therapeutics·Naveen TrehanAnupama R Kottam
Oct 19, 2016·Circulation·Barbara S WigginsUNKNOWN American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; C
Mar 17, 2016·Journal of the American Heart Association·Erin Rayner-Hartley, Tara Sedlak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.